Acromegaly – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Acromegaly Market Outlook

Thelansis’s “Acromegaly Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acromegaly treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Acromegaly Overview

Acromegaly is characterized by the progressive distortion of the body's features, primarily affecting the face and extremities but also impacting various organs throughout the body, resulting in systemic symptoms. It is closely linked to excessive growth hormone (GH) production. In over 90% of cases, this overproduction is triggered by a benign pituitary tumor called an adenoma. Due to its subtle onset and gradual progression, acromegaly is frequently not diagnosed until four to more than ten years after it begins, typically occurring in middle age, with the average age of onset ranging from 40 to 50 years. The prominent clinical signs include enlarged hands and feet, thickened and shortened fingers and increased soft tissue. The facial features include a broadened and consolidated nose, pronounced cheekbones, bulging forehead, thickened lips, and prominent facial lines. The forehead and overlying skin can become thicker, leading to a protruding appearance. There is a tendency for the jaw to overgrow, resulting in prognathism, widened maxilla, tooth spacing, and misalignment of the jaw. Furthermore, acromegaly has far-reaching implications for rheumatological, cardiovascular, respiratory, and metabolic health, significantly impacting its prognosis. Acromegaly is often associated with a pituitary adenoma, either exclusively secreting GH (60%) or mixed with other hormones. In exceedingly rare cases, it can result from the ectopic release of growth hormone-releasing hormone (GHRH), which leads to pituitary hyperplasia. The AIP gene (11q13.3) has been recognized as a significant predisposing factor, particularly when acromegaly emerges in childhood or adolescence. Additionally, acromegaly can be part of various endocrine neoplasia syndromes like MEN1 (MEN1 gene, 11q13), Carney complex (PRKAR1A gene, 17q24.2), or familial isolated pituitary adenoma (FIPA; AIP gene, 11q13.2). In rare cases, X-linked acrogigantism due to Xq26 microduplication (XLAG) can cause early-onset gigantism. Acromegaly may also be associated with McCune-Albright syndrome. The clinical diagnosis is confirmed through biochemical assessments, including elevated insulin-like growth factor-I (IGF-I) levels in the blood (used as a screening test) and increased GH levels in response to an oral glucose tolerance test (OGTT; used for confirmation). Imaging studies are employed to assess the size and extent of the tumor. Echocardiography and sleep apnea testing help gauge the clinical impact of acromegaly. The differential diagnosis encompasses other causes of acromegaly (such as FIPA, MEN1, Carney complex, and XLAG) and conditions like pachydermoperiostosis and acromegaloid features associated with severe insulin resistance. Most cases of acromegaly can be effectively managed hormonally, allowing patients to achieve a life expectancy similar to the general population. However, even in cases of cure or effective control, some long-term effects like joint pain, deformities, and alterations in quality of life may persist. Transsphenoidal surgery is typically the initial treatment choice. If surgery fails to normalize GH/IGF-I levels, medical treatments involving dopamine agonists and somatostatin analogs are recommended. Radiotherapy may be considered as a third-line treatment option if medical therapy is ineffective.

• The global prevalence of acromegaly is estimated at approximately 5.9 cases per 100,000 people.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: